- Published at
- by seekingalpha.com
neutral
neutral
Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT)
RAPT Therapeutics pivoted from a failed inflammation asset (RPT193) to focus on RPT904 for food allergies. Find out whether RAPT stock is a buy.